Other cancers, such as multiple myeloma, have been shown to be dependent on IRF4, and in this context depletion of IRF4 or treatment with an IRF4 inhibitor has been shown to induce lethality [58]. The gene discussed is IRF4; the disease is plasma cell myeloma.